Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2
Status:
Completed
Trial end date:
2018-04-12
Target enrollment:
Participant gender:
Summary
Trastuzumab is an important treatment for HER 2 positive breast cancer. But trastuzumab can
cause injury to the heart, and this is one of the main reasons it cannot be administered as
planned. Heart injury can often be successfully treated using cardiac medications. The aim of
SCHOLAR is to evaluate whether it is safe to continue trastuzumab in individuals with mild or
moderate cardiac injury, while treating them with appropriate cardiac medications. In this
way the investigators hope to be able to optimise the delivery of a treatment to patients
with breast cancer that has proven survival benefits, especially when administered for a full
12-month course.